Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity

References

• World Health Organization. Vaccines against influenza: WHO position paper – May 2022: World Health Organization; 2022 [cited 2023 Apr 6]. Available from: https://www.who.int/publications/i/item/who-wer9719
   Google Scholar
• World Health Organization. Influenza (Seasonal) 2023 [cited 2023 2 Jun]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
   Google Scholar
• European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. 2022 [cited 2022 Jul 26]. Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
   Google Scholar
• Collaborators GBDI. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global burden of disease study 2017. Lancet Respir Med. 2019 Jan;7(1):69–89. doi: 10.1016/S2213-2600(18)30496-X
   PubMed Web of Science ®Google Scholar
• Fischer WA, Gong M, Bhagwanjee S, et al. Global burden of influenza: contributions from resource limited and low-income settings. Global Heart. 2014;9(3):325. doi: 10.1016/j.gheart.2014.08.004
   PubMedGoogle Scholar
• Uyeki TM, Hui DS, Zambon M, et al. Influenza. Lancet. 2022 Aug 27;400(10353):693–706. doi: 10.1016/S0140-6736(22)00982-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. Flu news Europe: 2022-2023 season overview 2023 [cited 2023 Apr 5]. Available from: https://flunewseurope.org/SeasonOverview
   Google Scholar
• Li T, Asakawa T, Liu H, et al. The role of influenza in the era of COVID-19: can we forget it? Biosci Trends. 2022 Nov 20;16(5):374–376. doi: 10.5582/bst.2022.01297
   PubMedGoogle Scholar
• Talbot HK, Zhu Y, Chen Q, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis. 2013 Jun;56(12):1774–1777. doi: 10.1093/cid/cit124
   PubMed Web of Science ®Google Scholar
• Thompson MG, Pierse N, Sue Huang Q, et al. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015. Vaccine. 2018 Sep 18;36(39):5916–5925. doi: 10.1016/j.vaccine.2018.07.028
   PubMed Web of Science ®Google Scholar
• Casado I, Dominguez A, Toledo D, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Rev Vaccines. 2016;15(3):425–432. doi: 10.1586/14760584.2016.1134328
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Thompson MG, Blanton L, et al. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine. 2021 Jun 23;39(28):3678–3695. doi: 10.1016/j.vaccine.2021.05.011
   PubMed Web of Science ®Google Scholar
• Godoy P, Romero A, Soldevila N, et al. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro Surveill. 2018 Oct;23(43). doi: 10.2807/1560-7917.ES.2018.23.43.1700732
   PubMedGoogle Scholar
• Klein EY, Schueller E, Tseng KK, et al. The impact of influenza vaccination on antibiotic use in the United States, 2010-2017. Open Forum Infect Dis. 2020 Jul;7(7):ofaa223. doi: 10.1093/ofid/ofaa223
   PubMed Web of Science ®Google Scholar
• Vora A, Di Pasquale A, Kolhapure S, et al. The need for vaccination in adults with chronic (noncommunicable) diseases in India - lessons from around the world. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052544. doi: 10.1080/21645515.2022.2052544
   PubMed Web of Science ®Google Scholar
• Bhugra P, Grandhi GR, Mszar R, et al. Determinants of influenza vaccine uptake in patients with cardiovascular disease and strategies for improvement. J Am Heart Assoc. 2021 Aug 3;10(15):e019671. doi: 10.1161/JAHA.120.019671
   PubMed Web of Science ®Google Scholar
• World Health Organization. Seasonal influenza vaccines: an overview for decision-makers. 2020.
   Google Scholar
• European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU/EEA member States. 2018 [cited 2022 May 10]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/seasonal-influenza-antiviral-use-2018.pdf
   Google Scholar
• Preaud E, Durand L, Macabeo B, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014 Aug 7;14(1):813. doi: 10.1186/1471-2458-14-813
   PubMedGoogle Scholar
• Tisa V, Barberis I, Faccio V, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg. 2016;57(1):E28.
   PubMedGoogle Scholar
• Dolin R. The quadrivalent approach to influenza vaccination. J Infect Dis. 2013 Aug 15;208(4):539–540. doi: 10.1093/infdis/jit264
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012 Jan;8(1):81–88. doi: 10.4161/hv.8.1.17623
   PubMed Web of Science ®Google Scholar
• Tran D, Vaudry W, Moore D, et al. Hospitalization for influenza a versus B. Pediatrics. 2016 Sep;138(3). doi: 10.1542/peds.2015-4643
   PubMed Web of Science ®Google Scholar
• Karve S, Meier G, Davis KL, et al. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013 Jul 18;31(33):3370–3388. doi: 10.1016/j.vaccine.2013.04.081
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Types of seasonal influenza vaccine 2023 [cited 2023 Jul 27]. Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine
   Google Scholar
• van de Witte SV, Nauta J, Giezeman-Smits KM, et al. Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity. Trials Vaccinol. 2012;1:42–48. doi: 10.1016/j.trivac.2012.10.001
   Google Scholar
• van de Witte S, Nauta J, Montomoli E, et al. A phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine. 2018 Sep 25;36(40):6030–6038. doi: 10.1016/j.vaccine.2018.04.043
   PubMed Web of Science ®Google Scholar
• Vesikari T, Nauta J, Lapini G, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study. Int J Infect Dis. 2020 Mar;92:29–37. doi: 10.1016/j.ijid.2019.12.010
   PubMed Web of Science ®Google Scholar
• Esposito S, Nauta J, Lapini G, et al. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: a global, multiseasonal, controlled, randomized phase III study. Vaccine. 2022 Apr 20;40(18):2626–2634. doi: 10.1016/j.vaccine.2022.02.088
   PubMed Web of Science ®Google Scholar
• Kalappanavar NK, Ghosh A, Sharma M, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India. Human Vaccines Immunother. 2022;18(6). doi: 10.1080/21645515.2022.2104527
   PubMed Web of Science ®Google Scholar
• Basu I, Agarwal M, Shah V, et al. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - a phase III, active-controlled, randomized clinical study. Hum Vaccin Immunother. 2022 Dec 31;18(1):1–10. doi: 10.1080/21645515.2021.1885278
   PubMed Web of Science ®Google Scholar
• Moeller-Arendt M, van de Witte S, Nauta J, et al. Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: results from seven consecutive seasons. Vaccine. 2023 Jan 9;41(2):606–613. doi: 10.1016/j.vaccine.2022.12.001
   PubMed Web of Science ®Google Scholar
• Yamane N, Odagiri T, Arikawa J, et al. Effect of specific immunity to viral neuraminidase on subsequent influenza virus infection in man. Microbiol Immunol. 1979;23(6):565–567. doi: 10.1111/j.1348-0421.1979.tb00497.x
   PubMed Web of Science ®Google Scholar
• Giurgea LT, Morens DM, Taubenberger JK, et al. Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine. Vaccines (Basel). 2020 Jul 23;8(3):409. doi: 10.3390/vaccines8030409
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013 Jun 15;207(12):1878–87. doi: 10.1093/infdis/jit091
   PubMed Web of Science ®Google Scholar
• Hartvickson R, Cruz M, Ervin J, et al. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial. Int J Infect Dis. 2015 Dec;41:65–72.
   PubMed Web of Science ®Google Scholar
• Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis. 2013 Jul 24;13(1):343. doi: 10.1186/1471-2334-13-343
   PubMedGoogle Scholar
• Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 2015 May 15;33(21):2485–2492. doi: 10.1016/j.vaccine.2015.03.065
   PubMed Web of Science ®Google Scholar
• Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. The Lancet Child Adol Health. 2018;2(5):338–349. doi: 10.1016/S2352-4642(18)30062-2
   Web of Science ®Google Scholar
• Pepin S, Dupuy M, Borja-Tabora CFC, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: a multi-season randomised placebo-controlled trial in the northern and southern hemispheres. Vaccine. 2019 Mar 22;37(13):1876–1884. doi: 10.1016/j.vaccine.2018.11.074
   PubMed Web of Science ®Google Scholar
• Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. PharmacoEconomics. 2008;26(11):911–924. doi: 10.2165/00019053-200826110-00004
   PubMed Web of Science ®Google Scholar
• Leeb A, Carcione D, Richmond PC, et al. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults. Vaccine. 2011 Oct 19;29(45):7920–7924. doi: 10.1016/j.vaccine.2011.08.073
   PubMed Web of Science ®Google Scholar
• Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig. 1998;15(1):1–12. doi: 10.2165/00044011-199815010-00001
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013 Jan 21;31(5):770–776. doi: 10.1016/j.vaccine.2012.11.074
   PubMed Web of Science ®Google Scholar
• Airey J, Albano FR, Sawlwin DC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine. 2017;35(20):2745–2752. doi: 10.1016/j.vaccine.2017.03.028
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang L, Aggarwal N, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: a randomized, double-blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infect Dis Soc. 2015 Sep;4(3):242–51. doi: 10.1093/jpids/piu098
   PubMed Web of Science ®Google Scholar
• Pepin S, Szymanski H, Rochin Kobashi IA, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: a phase III randomized controlled study. Hum Vaccin Immunother. 2016 Dec;12(12):3072–3078. doi: 10.1080/21645515.2016.1212143
   PubMed Web of Science ®Google Scholar
• Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013 May 20;13(1):224. doi: 10.1186/1471-2334-13-224
   PubMedGoogle Scholar
• Sheffield JS, Greer LG, Rogers VL, et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol. 2012 Sep;120(3):532–537. doi: 10.1097/AOG.0b013e318263a278
   PubMed Web of Science ®Google Scholar
• Thompson MG, Kwong JC, Regan AK, et al. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016. Clin Infect Dis. 2019 Apr 24;68(9):1444–1453. doi: 10.1093/cid/ciy737
   PubMed Web of Science ®Google Scholar
• Lu QC, Zhang TY, Bundhun PK, et al. One “misunderstood” health issue: demonstrating and communicating the safety of influenza a vaccination in pregnancy: a systematic review and meta-analysis. BMC Public Health. 2021 Apr 9;21(1):703. doi: 10.1186/s12889-021-10740-w
   PubMed Web of Science ®Google Scholar
• Mehrabadi A, Dodds L, MacDonald NE, et al. Association of Maternal influenza vaccination during pregnancy with early childhood health outcomes. JAMA. 2021 Jun 8;325(22):2285–2293. doi: 10.1001/jama.2021.6778
   PubMed Web of Science ®Google Scholar
• Wagenhauser I, Mees J, Reusch J, et al. Determinants of Influenza A infection rate in post-COVID-19 era. J Infect. 2023 Oct;87(4):361–364. doi: 10.1016/j.jinf.2023.08.003
   PubMed Web of Science ®Google Scholar
• Van Ranst M, Zollner Y, Schelling J, et al. The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems. Expert Rev Vaccines. 2023 Jan;22(1):518–519. doi: 10.1080/14760584.2023.2221345
   PubMed Web of Science ®Google Scholar
• Welch VL, Metcalf T, Macey R, et al. Understanding the Barriers and Attitudes toward Influenza Vaccine Uptake in the Adult General Population: A Rapid Review. Vaccines (Basel). 2023 Jan 13;11(1):180. doi: 10.3390/vaccines11010180
   PubMed Web of Science ®Google Scholar
• Schmid P, Rauber D, Betsch C, et al. Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. PLoS One. 2017;12(1):e0170550. doi: 10.1371/journal.pone.0170550
   PubMed Web of Science ®Google Scholar
• Chen C, Liu X, Yan D, et al. Global influenza vaccination rates and factors associated with influenza vaccination. Int J Infect Dis. 2022 Dec;125:153–163.
   PubMed Web of Science ®Google Scholar
• Pahmeier K, Speckemeier C, Neusser S, et al. Vaccinating the German population aged 60 years and over with a quadrivalent high-dose inactivated influenza vaccine compared to standard-dose vaccines: a transmission and budget impact model. PharmacoEconomics. 2023 Nov;41(11):1539–1550. doi: 10.1007/s40273-023-01299-y
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season 2023 [cited 2023 Nov 7]. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season
   Google Scholar
• Caini S, Meijer A, Nunes MC, et al. Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases. 2023.
   Google Scholar